On this page
The April 2024 record describes different activities
Philips Respironics supplies sleep and respiratory-care devices. The FDA reported on 9 April 2024 that a court-entered consent decree restricted production and sale of certain new devices at named U.S. facilities, with exceptions and conditions. It also required a recall-remediation plan. Philips’ subsequent announcement described continuing support for installed devices under agreed conditions.
This is a historical, case-specific record. It does not establish the company’s status today or allow another business to assume that its own sales, repairs or exports may continue.
Replace “open or closed” with a list of actual work
For an owner, one broad label can hide two opposing mistakes: promising new work that is restricted, or withdrawing resources from customer obligations that remain. Start by separating new sales, production, servicing, replacement parts and any required customer remedy.
Use this ELN activity map with the people responsible for the actual requirements. A lawyer or suitable regulatory specialist must establish the scope for your circumstances; the table does not supply permission.
| Activity to separate | Evidence to establish | Operational question |
|---|---|---|
| New product sales | The exact product, entity, location and applicable restriction or permission | Who can approve a new commitment, and on what evidence? |
| Installed-customer support | The service activities and conditions actually permitted or required | Which people, parts and records must remain available? |
| Recall or other remedy | The applicable customer process and outstanding work | Who contacts customers and tracks unresolved cases? |
| Restart or expansion | The specific conditions and evidence needed before the activity resumes | Who can confirm readiness without relying on an internal target date? |
Budget the work that remains after the sale
Fictional example: an equipment business pauses new orders, but installed customers still need an agreed support route. Removing the technical team immediately would leave the customer plan without anyone able to carry it out. Keeping the whole sales organisation unchanged might also be unnecessary. The activity list helps management distinguish these decisions.
Price the retained people, records, parts and outside advice over the expected period. Keep uncertain timing visible rather than presenting an internal restart target as an approved date. A cash plan should show the continuing obligations alongside any interruption to new receipts.
Ask for a dated operating boundary
Request one dated record showing the affected activity, the authority or specialist evidence for its status, the accountable manager and the next decision. Give customer communication its own owner so a changing operating plan does not become an unsupported promise.
Use Launch dependencies to track the remaining conditions and customer work. Read the original FDA and company records for this historical case; current medical-device questions need current, product-specific official instructions.
Scope
- This account concerns the April 2024 Philips Respironics record. It is not a current sales-status finding, clinical advice or a complete statement of the decree.
- ELN’s activity map is an original management exercise. The actual scope and permission for another business require current, case-specific specialist checks.
Next step
In Launch dependencies, separate restricted activities, continuing customer work and restart conditions. Name the evidence, accountable person and funding needed for each.
Sources & review notes
U.S. Food and Drug Administration
Passage, dates and research notes
official-agency-report · 9 April 2024 announcement: restricted production/sales, specified exceptions and recall-remediation obligations
Read the full announcement, including exceptions and the conditions for resuming covered operations. This is historical case-specific agency reporting, not a present-status finding, clinical recommendation or rule for another business.
Royal Philips
Passage, dates and research notes
company-announcement · 10 April 2024 announcement: continued support under agreed conditions and restrictions on new U.S. device sales
Read the full dated company announcement. No recall-completion percentage, device-safety claim, financial forecast or current sales status is adopted as independently verified evidence.
Bookmark this guide or mark it as read.
Progress privacy
Saving is off by default. Without it, progress lasts only on this page. If you turn it on, this browser profile stores public content IDs and the progress you record. Anyone sharing the profile could see them. No plan inputs or contact details are included. Reset or export in learning settings.
This is a reading aid, not evidence of disclosure delivery, expertise or legal approval.